Table 2 Intervention details

Alyami et al. [27]

Gastric, Colon, Ovarian, Mesothelioma, Pseudomyxoma and others

Oxa, C/D or mito-c

NR

NR

Demtröder et al. [28]

Colorectal

Oxa

NR

6 weeks^a

Falkenstein et al. [29]

Biliary tract

C/D

NR

6 weeks^a

Graversen et al. [30]

Pancreatic

C/D

Gem + S-1

4–6 weeks^a

Hilal et al. [31]

Gynecological

C/D

NR

4–6 weeks^a

Khomyakov et al. [24]

Gastric

C/D

XELOX

6 weeks^a

Khosrawipour et al. [32]

Pancreatic

C/D

Gem+nab-Pax

Folfirinox

Gem

6 weeks^a

Nadiradze et al. [33]

Gastric

C/D

NR

6 weeks^a

Reymond et al. [34]^a

CUP, Pancreatic and Gallbladder

C/D

Cis + Gem

6 weeks^a

Robella et al. [26]

Mesothelioma, Ovarian, Colorectal, Pseudomyxoma and Gastric

C/D or Oxa

Topotecan

Folfox+cetuximab

Folfoxiri

Paclitaxel

Folfiri

Paclitaxel+Ramcirumab

Xelox

Paclitaxel

Pemetrexed

6 weeks^a

Farinha et al. [35]

Gynecological, Colorectal, Gastric, Small bowel, Appendix, Pseudomyxoma and Mesothelioma

NR

NR

6 weeks^a

Hübner et al. [36]

Gynecological and Digestive

C/D or OXA

NR

6 weeks^a